Atypical antipsychotics: newer options for mania and maintenance therapy (Q36158824)

12 August 2017

1 reference

title

Atypical antipsychotics: newer options for mania and maintenance therapy (English)

1 reference

12 August 2017

Eduard Vieta

1

0 references

author name string

Jose M Goikolea

series ordinal

2

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

7 Suppl 4

1 reference

12 August 2017

page(s)

21-33

1 reference

Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group

12 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Quality of life assessment in patients with bipolar disorder treated with olanzapine added to lithium or valproic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Olanzapine in the acute treatment of bipolar I disorder with a history of rapid cycling

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Acute and continuation risperidone monotherapy in mania.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Quetiapine in the treatment of rapid cycling bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Clinical factors associated with treatment noncompliance in euthymic bipolar patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Psychological interventions in bipolar disorder: From wishful thinking to an evidence-based approach

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Olanzapine versus divalproex in the treatment of acute mania

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Aripiprazole: profile on efficacy and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Efficacy of newer generation antipsychotics in the treatment of schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

Improving outcome in schizophrenia: the potential importance of EPS and neuroleptic dysphoria

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1399-5618.2005.00212.X

10.1111/J.1399-5618.2005.00212.X

21 January 2018

Identifiers

DOI

1 reference

12 August 2017

1 reference